BCR and leukemia: In particular there are potential implications for TFR, even preventing the emergence of BCR-ABL1 compound mutations in advanced Ph+ leukemias treated with 3G TKI ponatinib, thus further improving long-term outcomes of patients with CML and Ph+ ALL.